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Objectives The purpose of this study was to define the clinical characteristics and long-term follow-up of pediatric patients
with short QT syndrome (SQTS).
Background SQTS is associated with sudden cardiac death. The clinical characteristics and long-term prognosis in young pa-
tients have not been reported.
Methods This was an international case series involving 15 centers. Patients were analyzed for electrocardiography char-
acteristics, genotype, clinical events, Gollob score, and efficacy of medical or defibrillator (implantable
cardioverter-defibrillator [ICD]) therapy. To assess the possible prognostic value of the Gollob score, we devised a
modified Gollob score that excluded clinical events from the original score.
Results Twenty-five patients 21 years of age or younger (84% males, median age: 15 years, interquartile range: 9 to 18
years) were followed up for 5.9 years (interquartile range: 4 to 7.1 years). Median corrected QT interval for heart rate
was 312 ms (range: 194 to 355 ms). Symptoms occurred in 14 (56%) of 25 patients and included aborted sudden
cardiac death in 6 patients (24%) and syncope in 4 patients (16%). Arrhythmias were common and included atrial
fibrillation (n  4), ventricular fibrillation (n  6), supraventricular tachycardia (n  1), and polymorphic ventricular
tachycardia (n  1). Sixteen patients (84%) had a familial or personal history of cardiac arrest. A gene mutation asso-
ciated with SQTS was identified in 5 (24%) of 21 probands. Symptomatic patients had a higher median modified
Gollob score (excluding points for clinical events) compared with asymptomatic patients (5 vs. 4, p  0.044). Ten pa-
tients received medical treatment, mainly with quinidine. Eleven of 25 index cases underwent ICD implantation. Two
patients had appropriate ICD shocks. Inappropriate ICD shocks were observed in 64% of patients.
Conclusions SQTS is associated with aborted sudden cardiac death among the pediatric population. Asymptomatic pa-
tients with a Gollob score of 5 remained event free, except for an isolated episode of supraventricular
tachycardia, over an average 6-year follow-up. A higher modified Gollob score of 5 or more was associated
with the likelihood of clinical events. Young SQTS patients have a high rate of inappropriate ICD
shocks. (J Am Coll Cardiol 2013;61:1183–91) © 2013 by the American College of Cardiology Foundation
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Pediatric Short QT Syndrome March 19, 2013:1183–91The short QT syndrome (SQTS) is
a primary cardiac electrical disease
and one of the recent additions of
inherited arrhythmias associated
with sudden cardiac death (SCD).
Although believed to be a rare con-
dition, the entire disease spectrum
continues to emerge with newly rec-
ognized cases, and as we continue to
understand the disease better and to
characterize it more fully, a broader
disease spectrum may be revealed.
The underlying pathophysiological
features involve shortening of myo-
cardial repolarization, which creates
the electrical substrate for atrial and
ventricular tachyarrhythmias (1).
The arrhythmogenic potential of a short QT interval was de-
scribed first by Gussak et al. (2). To date, genetic studies have
shown that SQTS is associated with gain-of-function mutations
in 3 different potassium channels (3–6) and 3 loss-of-function
mutations in the L-type cardiac calcium channel, although forms
of short QT interval associated with calcium channelopathies
show phenotypic overlap with Brugada syndrome (7,8).
In SQTS, the corrected QT interval for heart rate
using the Bazett formula (QTc) in most reported cases to
date usually is 340 to 360 ms, with rare exceptions (9).
A normal QT interval has been reported as 370  30 ms
in children (10) and 385  24 ms in adults (11), with a
slightly longer QT interval in post-pubescent females
(12). According to population studies (13), a QTc inter-
val of 340 to 360 ms has been proposed as the lower limit
of normal. However, as demonstrated with long QT
syndrome, there is an overlapping range of QT intervals
between affected individuals (14) and apparently healthy
subjects (15). It is likely SQTS cases with longer QTc
interval exist. In contrast, the presence of a short QT
interval in isolation may not always be indicative of
SQTS. Thus, Gollob et al. (16) proposed diagnostic
criteria for SQTS (Table 1).
The therapeutic approach to SQTS is not well defined.
An implantable cardioverter-defibrillator (ICD) may be
considered as primary therapy, given the known risk of SCD
(17). However, the risk-to-benefit ratio of such an approach
remains unknown, particularly in the young. Although
hydroquinidine has demonstrated some benefit in a limited
number of patients (18,19), there is limited experience with
medical therapy.
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Abbreviations
and Acronyms
ECG  electrocardiography
ICD  implantable
cardioverter-defibrillator
IQR  interquartile range
QTc  corrected QT
interval for heart rate using
the Bazett formula
SCD  sudden cardiac
death
SQTS  short QT syndrome
SVT  supraventricular
tachycardia
VF  ventricular fibrillationManuscript received October 4, 2012; revised manuscript received November 29,
2012, accepted December 11, 2012.To date, the long-term prognosis in young SQTS pa-
tients has not been reported. We set out to define the
clinical characteristics and long-term outcomes of a pediat-
ric cohort diagnosed with SQTS.
Methods
Study population. Pediatric SQTS patients (21 years of
age at clinical presentation) from 15 centers in North and
South America, Europe, and Japan were characterized
clinically and were followed up beginning in 2007. Entry
criteria included: 1) QT interval of 330 ms or less; or 2)
QTc interval of 360 ms or less with 1 or more of the
following: syncope, atrial fibrillation, ventricular fibrillation
(VF), aborted SCD, positive family history of SQTS or
unexplained SCD, or a combination thereof. A total of 28
patients were enrolled, of whom 25 met the inclusion
criteria for this study: 1) a Gollob diagnostic score of 3 or
more (indicating a moderate to high probability of SQTS);
and 2) clinical follow-up longer than 1 year. Patient demo-
graphic data were collected. The ECG parameters analyzed
included: QT interval, QTc interval, J point-to-T peak
interval, and early repolarization. The QT interval was
measured manually. The QTc interval was calculated using
Bazett’s formula. The J point was defined as the end of the
QRS interval and the beginning of the ST segment. The T
peak was measured at the highest point of the T-wave. Early
repolarization was defined as an elevation of more than 0.1
mV of the J point from baseline in at least 2 contiguous
SQTS Diagnostic Criteria: Gollob ScoreTable 1 SQTS Diagnostic Criteria: Gollob Score
Points
QTc interval (ms)
370 1
350 2
330 3
J point-to-T peak interval 120 ms 1
Clinical history*
History of sudden cardiac arrest 2
Documented polymorphic VT or VF 2
Unexplained syncope 1
Atrial fibrillation 1
Family history*
First- or second-degree relative with high-probability SQTS 2
First- or second-degree relative with autopsy-negative
sudden cardiac death
1
Sudden infant death syndrome 1
Genotype*
Genotype positive 2
Mutation of undetermined significance in a culprit gene 1
High-probability SQTS: 4 points, intermediate-probability SQTS: 3 points, low-probability SQTS:
2 points. Electrocardiogram must be recorded in the absence of modifiers known to shorten the
QT interval. J point-to-T peak interval must be measured in the precordial lead with the greatest
amplitude T-wave. Clinical history events must occur in the absence of an identifiable cause,
including structural heart disease. Points can be received only for 1 of cardiac arrest, documented
polymorphic VT, or unexplained syncope. Family history points can only be received once in this
section. *A minimum of 1 point must be obtained in the electrocardiographic section to obtain
additional points.QTc corrected QT interval for heart rate using the Bazett formula; SQTS short QT syndrome;
VF  ventricular fibrillation; VT  ventricular tachycardia.
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March 19, 2013:1183–91 Pediatric Short QT Syndromeleads in the inferior leads (II, III, aVF), lateral leads (I, aVL,
V4 to V6), anterior leads (V1 to V3), or combinations
thereof. The contour of the ST segment was classified as
having either upsloping or horizontal (downsloping) mor-
phological features. Patients with ICD were assessed for
implant indication, delivered therapies, and device compli-
cations. We elected to explore the risk-stratifying value of
specific variables within the Gollob scoring system. Thus,
the diagnostic Gollob score was modified, by excluding
clinical events, into a new prognostic score referred to as the
modified Gollob score (Table 2).
Statistical analysis. Continuous variables are presented as
mean  SD or median (interquartile range [IQR]: 25th to
75th percentile). Analyzed continuous variables are pre-
sented only as medians with IQR and were analyzed using
the Wilcoxon rank sum test. Categorical variables are
presented as counts with percentages and were analyzed
using the Fisher exact test or the chi-square test. Correla-
tion between continuous data was analyzed using the
Spearman correlation coefficient. Two-tailed p values of
0.05 were considered statistically significant. Statistical
analysis was performed using SAS software version 9.3
(SAS Institute, Inc., Cary, North Carolina).
Results
Clinical data. There were 25 patients and a total of 21
(84%) were male. Their clinical data are presented in Table 3.
Patients were followed up for a median of 5.9 years (IQR: 4
to 7.1 years). Patient age at the time of clinical presentation
ranged from 1 day to 21 years (13.4  6 years, median: 15
years, IQR: 9 to 18 years), with 9 patients (36%) younger
than 12 years.
ECG. The QT interval varied from 160 to 360 ms (279  51
s, median: 290 ms, IQR: 280 to 300 ms), whereas the QTc
SQTS Diagnostic Criteria: Modified Gollob ScoreTable 2 SQTS Diagnostic Criteria: Modified Gollob Score
Points
QTc interval (ms)
370 1
350 2
330 3
J point-to-T peak interval 120 ms 1
Family history*
First- or second-degree relative with high-probability SQTS 2
First- or second-degree relative with autopsy-negative sudden
cardiac death
1
Sudden infant death syndrome 1
Genotype*
Genotype positive 2
Mutation of undetermined significance in a culprit gene 1
Electrocardiogram must be recorded in the absence of modifiers known to shorten the QT interval.
J point-to-T peak interval must be measured in the precordial lead with the greatest amplitude
T-wave. Family history points can be received only once in this section. *Aminimum of 1 point must
be obtained in the electrocardiographic section to obtain additional points.
Abbreviations as in Table 1.nterval ranged from 194 to 355 ms (304  41 ms, median:12 ms, IQR: 286 to 335 ms). The J point-to-T peak interval
anged from 63 to 180 ms (132  35 ms, median: 140 ms,
QR: 119 to 160 ms). Arrhythmias were common: 4 patients
ad atrial fibrillation, 6 had VF, and 1 had supraventricular
achycardia (SVT) at presentation.
GENETIC TESTING. Genetic testing was undertaken in 21
of the 25 patients, and 5 patients had a confirmed mutation.
All gene-positive patients were symptomatic, including a
3-month-old young female with recurrent atrial fibrillation
since the age of 4 days and associated sinus and atrioven-
tricular node dysfunction (KCNQ1 V141M). Tables 3 and 4
outline the culprit genes, specific mutations, and associated
symptoms and arrhythmias detected in the gene-positive
cohort.
FAMILY HISTORY. A personal or familial history of cardiac
arrest was present in 16 (84%) of 25 patients. A familial
history of SCD, presumed to be arrhythmogenic, was
present in 5 symptomatic patients and in 6 asymptomatic
patients. These involved 6 siblings (4 young males and 2
young females), 2 uncles, and 1 father. The equal distribu-
tion of familial SCD among symptomatic and asymptom-
atic individuals suggests that SCD alone may not predict
prognosis, although numbers were relatively small in this
study. Among the entire cohort, there was a positive family
history for a clinical diagnosis of SQTS in 17 (68%)
patients, equally distributed between parents and siblings.
Among the patients with atrial fibrillation, only 1 of 4 had
a family history of atrial fibrillation. In the patients with VF,
only 1 of 6 had a first-degree relative (father) with SCD.
Overall, the prevalence of symptomatic family members did
not seem to be more common in symptomatic patients,
although a much larger cohort would be required to assess
confidently whether a symptomatic family member predicts
individual risk. Only 4 of 25 patients had no family history
of SQTS or SCD.
Symptomatic versus asymptomatic patients. Of the en-
tire cohort, 14 (56%) patients had 1 or more clinical features
associated with SQTS, including aborted SCD in 6 (24%),
unheralded syncope in 4 (16%), and palpitations with
documented atrial fibrillation in 4 (16%). The remaining 11
(44%) patients were asymptomatic, 10 of whom were
identified through family screening and the remaining
through an incidental ECG finding of a very short QTc
interval (292 ms). There was no significant difference in
median age between symptomatic and asymptomatic pa-
tients (median: 15 years, IQR: 8 to 17 years vs. median: 17
years, IQR: 9 to 18 years, p  0.621). All but 1 of the
asymptomatic cases had a family history of SQTS or
unexplained SCD.
ECG PARAMETERS. No differences were found in the ECG
parameters between asymptomatic and symptomatic pa-
tients (Table 3). Although the QTc interval tended to be
shorter in symptomatic patients (median: 306 vs. 330 ms),
the difference was not statistically significant (p  0.207).
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Pediatric Short QT Syndrome March 19, 2013:1183–91There was a trend toward a higher prevalence of short J
point-to-T peak interval (120 ms) in the symptomatic
versus the asymptomatic patients (42.9% vs. 9.1%, p 0.090).
Only 1 of the asymptomatic patients had a short J point-
to-T peak interval. The presence of early repolarization did
not differ between symptomatic and asymptomatic patients.
Early repolarization was found in the anterior (n  2),
anterolateral (n 2), lateral (n 1), and anteroinferolateral
(n  1) leads in 43% of symptomatic cases. In 60% of
asymptomatic cases, early repolarization was found in the
inferolateral (n 3) cases and in the anterior or lateral leads, or
both (n 3). In all cases, early repolarization had an upsloping
ST segment pattern (Fig. 1).
Characteristics of All PatientsTable 3 Characteristics of All Patients
Variable Total (n  25)
Patient age at presentation (yrs) 15 (9–18)
Age 12 yrs 9 (36%)
Male 21 (84%)
Follow-up duration (yrs) 5.9 (4.4–7.1)
Symptoms
Aborted SCD 6 (24%)
Unheralded syncope 4 (16%)
Palpitations† 4 (16%)
Modified Gollob score 5 (4–5)
Genetic mutation
KCNH2 2 (8%)
KCNJ2 2 (8%)
KCNQ1 1 (4%)
ECG parameters
QT (ms) 290 (280–300)
QTc (ms) 312 (286–335)
J point-to-T peak interval (ms) 140 (119–160)
J point-to-T peak interval 120 (ms) 7 (28%)
Early repolarization 12/24 (50%)
Family history
SQTS 8 (32%)
SCD 4 (16%)
SCD and SQTS 9 (36%)
Negative 4 (16%)
ICD 11 (44%)
Appropriate shocks 2 (18%)
Inappropriate shock 7 (63.6%)
Complications‡ 9 (81.8%)
Values aremedian (interquartile range) or n (%). *Only patients with aborted sudden cardiac death, s
symptomatic for short QT syndrome. †Palpitations and atrial fibrillation or supraventricular tachyc
ECG electrocardiography; ICD implanted cardiac defibrillator; J point-to-T peak interval in
oltage; SCD  sudden cardiac death. Other abbreviations as in Table 1.
Genetic Mutations in the Pediatric CohortTable 4 Genetic Mutations in the Pediatric Cohort
Age (yrs) Sex Gene Mutation Current
3 F KCNQ1 V141M IKs
5 F KCNJ2 M301K IK1
8 F KCNJ2 M301K IK1
14 M KCNH2 N588K IKr19 M KCNH2 E50D IKrGOLLOB DIAGNOSTIC SCORE FOR SQTS. Asymptomatic pa-
ients had Gollob scores ranging from 3 to 5 (median: 4,
QR: 4 to 5), whereas most symptomatic patients had
igher Gollob scores ranging from 4 to 10 (median: 6, IQR,
to 8, p  0.001).
A modified Gollob score, excluding clinical events, was
ssigned to each patient. Asymptomatic patients had mod-
fied Gollob scores ranging from 3 to 5 (median: 4, IQR: 4
o 5), whereas most symptomatic patients had higher scores
anging from 3 to 8 (median: 5, IQR: 4 to 6, p  0.044).
ABORTED SCD. Aborted SCD occurred in 6 (24%) of 25
patients. These patients had a longer follow-up duration
tomatic* (n  14) Asymptomatic (n  11) p Value
15 (8–17) 17 (9–18) 0.621
4 (28.6%) 5 (45.5%) 0.434
11 (78.6%) 10 (90.9%) 0.604
5.7 (4.8–7.4) 6.1 (3.2–6.9) 0.460
6 (43%) —
4 (28.5%) —
4 (28.5%) —
5 (4–6) 4 (4–5) 0.044
2 (14%) 0
2 (14%) 0
1 (7%) 0
280 (200–300) 295 (280–320) 0.333
306 (252–329) 330 (292–335) 0.207
130 (80–160) 140 (120–160) 0.344
6 (42.9%) 1 (9.1%) 0.090
/14 (43%) 6/10 (60%) 0.680
0.620
4 (28.6%) 4 (36.4%)
3 (21.4%) 1 (9.1%)
4 (28.6%) 5 (45.5%)
3 (21.4%) 1 (9.1%)
8 (57.1%) 3 (27.3%) 0.227
2 (25%) 0
4 (50%) 3 (100%)
6 (75%) 3 (100%)
, or documented ventricular or atrial fibrillation at presentation or during follow-up were considered
‡Including inappropriate shocks.
milliseconds measured on standard electrocardiography ECG from the J-point to the peak T-wave
Symptoms Arrhythmias
None Atrial fibrillation, sinus, and atrioventricular node dysfunction
None Atrial fibrillation
None Atrial fibrillation
Syncope Ventricular fibrillationSymp
6
yncope
ardia.Syncope None
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March 19, 2013:1183–91 Pediatric Short QT Syndromethan those without aborted SCD (median: 7.3 years, IQR:
6.3 to 7.8 years vs. median: 5.3 years, IQR: 4.0 to 6.9 years,
p 0.045). A short J point-to-T peak (120 ms) was more
prevalent among the aborted SCD group (67% vs. 16%, p
0.032) (Table 5). Five of these 6 patients had implantation
of an ICD. In one instance, the parents declined an ICD for
a 6-month-old young male (at the time of clinical presen-
tation) with an ultra-short QT interval of 160 ms (QTc
interval: 241 ms) who, at 80 months of follow-up, had no
recurrent symptoms (Fig. 2). A positive family history of
SQTS or SCD did not discriminate between aborted SCD
and nonaborted SCD patients because of the high preva-
lence among the entire cohort. Early repolarization with
upsloping ST segment in the anteroinferolateral leads was
present in only 1 of the 6 patients with aborted SCD.
Therapy. ICD. Implantation of a cardioverter-defibrillator
(ICD) was performed in 11 (44%) of 25 patients, in 6 as
primary prevention (unexplained syncope in 2). Indications
for ICD in the other 5 patients were aborted SCD or VF.
Two (18%) patients had appropriate shocks: a 14-year-old
young male (QT interval: 300 ms, QTc interval: 286 ms)
with a history of aborted SCD while receiving quinidine at
9 mg/kg daily and a 14-year-old young male (QT interval:
248 ms; QTc interval: 252 ms) with a history of syncope and
VF. The latter had no recurrent ICD appropriate shocks
while taking quinidine. Two other patients had no shock
and 7 (64%) had 1 or more inappropriate shocks. The
underlying cause of inappropriate shocks was atrial fibrilla-
tion with rapid ventricular conduction (n  1), sinus
tachycardia (n  3), SVT (n  1), and ventricular lead
racture (n 3), including 1 Sprint Fidelis lead (Medtronic,
inneapolis, Minnesota). There was an additional patient
ith a ventricular lead fracture 6 years after implantation
hat did not cause an inappropriate ICD shock. Of patients
ho received an ICD as primary prevention, 4 had inap-
Figure 1 Representative 12-Lead Electrocardiogram of the Sho
Resting electrocardiogram (ECG) of a 15-year-old young male with aborted sudden
heart rate [QTc]: 325 ms). There are peaked T waves in most of the precordial lea
ing ST segment in II, III aVF, and V2 to V6.ropriate shocks.MEDICAL THERAPY. Medical therapy was initiated in 10
40%) of 25 patients, 4 of whom received multiple agents.
f the 4 patients with paroxysmal atrial fibrillation, 3
eceived quinidine therapy that proved unsuccessful in
reventing recurrences of the arrhythmia. These patients
ere quite young, including an infant who also had recur-
ences while receiving propafenone and sotalol, a 5-year-old
n whom flecainide also failed, and an 8-year-old. The
emaining patient with atrial fibrillation was a 17-year-old
oung male (QT interval: 320 ms, QTc interval: 355 ms)
Fig. 3A) who was cardioverted at the time of ICD
mplantation, but continued to experience recurrences de-
pite therapy with digoxin and propafenone. On treatment
ith digoxin and dofetilide, there was prolongation of the
T interval and return to sinus rhythm without symptom-
tic recurrences through follow-up (Fig. 3B). However,
CD interrogation identified asymptomatic, short episodes
f atrial fibrillation. Two patients with a history of appro-
riate ICD shocks also received quinidine therapy. The first
atient, a 14-year-old young male with aborted SCD, had a
herapeutic shock while receiving quinidine 9 mg/kg daily.
e were unable to confirm whether lack of compliance was
he issue. The J point-to-T peak interval in this patient was
18 ms. He had a Gollob score of 8 with a QT interval of
00 ms (QTc interval: 286 ms). Genetic testing did not
dentify any known mutation. The second patient had no
ecurrent shocks while receiving quinidine therapy.
ARRHYTHMIAS ENCOUNTERED DURING FOLLOW-UP. Of
the asymptomatic patients, only a 21-year-old man with an
ICD as primary prevention had SVT resulting in inappropriate
shocks and requiring ICD reprogramming. He had a modified
Gollob score of 4. The other 10 asymptomatic cases with
Gollob scores of 3 to 5 remained asymptomatic and
arrhythmia-free during follow-up. In the group that was
Syndrome
c death and a short QT interval (QT interval: 280 ms, QT interval corrected for
e J point-to-T peak interval is 140 ms. There is early repolarization with upslop-rt QT
cardia
ds. Thsymptomatic at presentation, a 19-year-old man receiving no
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Pediatric Short QT Syndrome March 19, 2013:1183–91medical therapy and with a history of aborted SCD experi-
enced 2 episodes of nonsustained polymorphic ventricular
tachycardia that terminated spontaneously. All cases with atrial
fibrillation required ongoing therapy with cardioversion, med-
ical treatment with different antiarrhythmic agents, or both. A
3-month-old young female with an ultra-short QT of 200 ms
(QTc interval: 275 ms) had a history of marked sinus brady-
cardia since birth and atrioventricular node dysfunction with a
Wenckebach cycle length of 500 ms. The patient demon-
strated atrial fibrillation at 4 days of age, requiring cardiover-
sion. A ventricular pacemaker was implanted at 6 days of age.
Despite antiarrhythmic therapy, it eventually progressed into
permanent atrial fibrillation. A 5-year-old young female with
an ultra-short QT of 172 ms (QTc interval: 194 ms) had
mechanically induced atrial and VF during insertion of a Swan
Ganz catheter.
Discussion
To our knowledge, this is the longest follow-up cohort of
Comparison of Patients With VersusWithout Aborted Sudden Cardiac DeathTable 5 Compariso of Patient With VersusWithout Aborted Sudden Cardiac Death
Variable
Aborted SCD
(n  6)
No Aborted SCD
(n  19) p Value
Patient age at
presentation (yrs)
14 (14–15) 17 (8–18) 0.632
Age 12 yrs 1 (16.7%) 8 (42.1%) 0.364
Male 6 (100%) 15 (79%) 0.540
Follow-up duration (yrs) 7.3 (6.3–7.8) 5.3 (4.0–6.9) 0.045
Genetic mutation (n  21)
KCNH2 1 (20%) 1 (6.3%)
KCNJ2 0 2 (12.5%)
KCNQ1 0 1 (6.3%)
Negative 4 (80%) 12 (75%)
Family history
SCD and/or SQTS 5 (83.3%) 16 (84.2%) 0.999
ECG parameters
QT interval (ms) 280 (248–300) 295 (280–320) 0.261
QTc interval (ms) 300 (252–325) 312 (291–335) 0.323
QTc interval  330 ms 5 (83.3%) 11 (57.9%) 0.364
J point-to-T peak interval 109 (80–140) 140 (120–160) 0.130
J point-to-T peak interval
120 ms
4 (66.7%) 3 (15.8%) 0.032
Early repolarization 1/6 (17%) 11/18 (61%) 0.155
Medical therapy with
quinidine
3 (50%) 6 (31.6%) 0.344
Documented arrhythmia
on follow-up
Ventricular fibrillation 1 (16.7%) 0
Polymorphic VT 1 (16.7%) 0
Atrial fibrillation 0 3 (15.8%)
SVT 0 1 (5.3%)
ICD 5 (83.3%) 6 (31.6%) 0.056
Appropriate shocks 2 (40%) 0
Inappropriate shock 3 (60%) 4 (66.7%)
Complications* 5 (100%) 4 (66.7%)
Values are median (interquartile range) or n (%). *Including inappropriate shocks.
SVT  supraventricular tachycardia; other abbreviations as in Tables 1 and 3.patients with SQTS reported in the literature. It alsorepresents the largest series of pediatric SQTS patients,
because the average age in this cohort was 13 years.
Our cohort was predominantly male (84%), reflecting a
sex-specific prevalence and possible greater vulnerability to
SQTS in young males as compared with young females.
Eighty-four percent of patients had a personal or familial
history of cardiac arrest. More than half of our patients had
symptoms, including aborted SCD (24%) and syncope
(16%). The most common symptomatic presentation was
cardiac arrest. An additional 11 cases (44% of cohort) were
identified through cascade family screening. Twenty percent of
cases were identified to have disease-causing mutations. Our
cohort included a 6-year-old young male with aborted SCD
and a QT interval of 160 ms, the shortest QT interval reported
to date. In addition, we report 3 children younger than 8 years
with recalcitrant atrial fibrillation and ultra-short QT intervals
ranging from 172 to 200 ms and 1 patient, an infant with a QT
of 200 ms (QTc interval: 275 ms), who had coexisting sinus
and atrioventricular node dysfunction. This patient had sinus
bradycardia at birth and demonstrated slow atrial fibrillation at
4 days of age. To our knowledge, the latter clinical scenario
associated with a V141M mutation in the KCNQ1 gene has
not been reported with SQTS. Another unique finding in this
young population has been the high incidence of inappropriate
shocks, affecting 64% of ICD recipients, which far exceeded
appropriate shocks.
A previously reported study presented the clinical char-
acteristics and outcomes in an adult population of SQTS
patients (median age: 26 years) (19). Similar to the obser-
vations of our pediatric cohort, most clinically affected
adults were men (75%), cardiac arrest as a first presentation
was relatively common (32%), a family history of SQTS was
present in 50% of patients, and disease-causing mutations
were found in 23% of probands. In contrast, our pediatric
cohort tended to have a shorter QTc interval (average: 304
ms vs. 314 ms), and although adult and pediatric ICD
recipients both received a high inappropriate shock rate, this
was more common in pediatric patients (64% vs. 33%).
Gollob et al. (16) proposed diagnostic criteria for SQTS.
We found that a modified Gollob score, which excluded points
for clinical events, may be useful in identifying patients at a
higher risk for unexplained syncope, atrial fibrillation, or
aborted SCD. Our patients with a history of these clinical
events had a median modified score of 5 (range: 4 to 6) as
compared with a median of 4 (range: 4 to 5) in patients who
remained asymptomatic (except 1 case of SVT). Patients with a
modified Gollob score of 3 (or Gollob score of 5) had a good
prognosis during follow-up in this study. Only 1 (7%) of 14
symptomatic patients had a low modified Gollob score of 3.
SQTS is considered a rare electrical abnormality, and
recognition of this condition as a cause of unexplained SCD
in young children is uncommon, although perhaps under-
recognized. A reported series of adult patients with idio-
pathic VF were noted to have a mean QTc value of 371 ms,
significantly less than the QTc value of healthy sex- and
age-matched controls (20). These observations suggest that
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SQTS disease spectrum.
Aborted SCD affected 6 of our patients (24%), 5 of them
at 15 years of age or younger. One of the current therapeutic
options for patients with SQTS includes implantation of an
ICD (21–23). Six of our patients received an ICD for
primary prevention; however, 4 experienced 1 or more
inappropriate ICD shocks. Previous studies have reported
an increased risk for inappropriate ICD therapy because of
oversensing of short-coupled and prominent T waves re-
sulting in T-wave oversensing (24). In our young cohort
with SQTS, inappropriate shocks far exceeded appropriate
shocks. Most of our patients had inappropriate shocks
secondary to atrial tachycardias, including sinus tachycardia
(n  3), SVT (n  1), and atrial fibrillation (n  1).
nappropriate therapies resulting from rapid atrial arrhyth-
ias may be prevented by programming device therapies for
eart rates exceeding 210 beats/min, although a formative
ssessment is needed to evaluate the efficacy of such an
pproach. In addition, we observed a high prevalence of
entricular lead fracture of 36% (4 of 11 cases) with most
3 of 4) resulting in inappropriate ICD shocks. The high
revalence of ventricular lead fracture in part may be the
esult of the patients’ young ages at implantation. These
oints together highlight our concerns regarding the use of
CD therapy in asymptomatic young patients.
We identified a higher prevalence of short J point-to-T
eak interval (120 ms) in symptomatic (42.9%) versus
symptomatic patients (9.1%). However, because of the
mall number of cases, the difference did not reach statistical
ignificance. Watanabe et al. (25) reported a high prevalence
65%) of early repolarization in patients with SQTS that
as associated with arrhythmic events. In their cohort, early
epolarization was localized in either inferior leads, lateral
eads, or both, but the ST segment contour was not
escribed in their paper. Early repolarization with upsloping
Figure 2 Extreme Abbreviation of QT Interval in a Young, Symp
An ultra-short QT interval of 160 ms (QTc interval: 241 ms) in a 6-month-old youngorphological features can be a benign ECG finding (26), Thereas a horizontal or downsloping ST segment may be
ssociated with VF (27). Early repolarization also was ob-
erved in a high percentage of our cohort (50%), and it was
ocalized in anterior, inferior, and lateral leads, or in a combi-
ation thereof. This ECG feature was not significantly differ-
nt between our symptomatic (43%) and asymptomatic (60%)
atients. None of our patients with early repolarization had a
orizontal or downsloping pattern. Only 1 of our 6 cases of
borted SCD showed early repolarization.
Five of our patients, all symptomatic, had genetic muta-
ions associated with SQTS. The yield of genetic mutation
etection was 24% for index patients who underwent
enetic testing. This compares with the 23% incidence
eported in the literature (16).
Quinidine has been suggested as one of the mainstay
herapies for SQTS because of its ability to offset the
xtreme shortening of repolarization that occurs in SQTS
28). In this cohort, quinidine proved ineffective in manag-
ng atrial fibrillation in those patients with frequent recur-
ences. In addition, while receiving a low dose of quinidine,
ne patient experienced a therapeutic ICD shock. There-
ore, the effectiveness of this antiarrhythmic agent in young
QTS patients awaits further investigation.
tudy limitations. Although we describe the largest pop-
lation of pediatric patients with SQTS with the longest
eported clinical follow-up, event rates and risks in later
ecades of life remain unknown. As a relatively rare or
erhaps under-recognized disease, our cohort included only
5 patients. Thus, we must be cautious in reaching conclu-
ions based on such a small group.
onclusions
QTS in the pediatric population is associated with a high
isk of aborted SCD. The diagnosis seems more common in
oung males similar to observations in adult SQTS patients.
tic Child
at the time of clinical evaluation after cardiac arrest.toma
malehis may reflect protection from ultra-short QT intervals in
1190 Villafañe et al. JACC Vol. 61, No. 11, 2013
Pediatric Short QT Syndrome March 19, 2013:1183–91women because of the QT prolonging effects of estrogen
(29). A modified Gollob score may be useful in identifying
patients at a higher risk of clinical events and may prove
useful for risk stratification, although larger cohort studies
are necessary. Although ICD therapy proved useful in some
patients, it was fraught with inappropriate shocks. One of 2
appropriate ICD shocks occurred despite a low dose of
quinidine. Quinidine monotherapy did not prove to be
effective in treating atrial fibrillation.
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Figure 3 Atrial Fibrillation and the Short QT Syndrome in a 17-Y
Conversion to Sinus Rhythm and Prolongation of the Q
(A) 12-lead ECG of a symptomatic 17-year-old young male with atrial fibrillation. Th
T waves, and early repolarization. (B) After treatment with dofetilide and digoxin, t
The patient remained asymptomatic and on sinus rhythm except for short bouts ojuanvillaf@yahoo.com.REFERENCES
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